Amicus Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $13 price target.
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics' stock (FOLD) trades higher following an upgrade from Neutral to Buy by Guggenheim, with a new price target set at $13.
May 14, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amicus Therapeutics' stock received a positive outlook from Guggenheim, upgrading it to Buy and setting a price target of $13, indicating a bullish sentiment.
The upgrade from Neutral to Buy by a reputable financial institution like Guggenheim typically leads to increased investor confidence and can drive the stock price up in the short term. The setting of a $13 price target further emphasizes the bullish outlook for Amicus Therapeutics, suggesting that the stock is currently undervalued and has significant upside potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100